View ValuationNovozymes 将来の成長Future 基準チェック /36Novozymes利益と収益がそれぞれ年間14%と6.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に8.9% 13.8%なると予測されています。主要情報14.0%収益成長率13.81%EPS成長率Chemicals 収益成長39.4%収益成長率6.6%将来の株主資本利益率8.93%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報お知らせ • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).お知らせ • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).お知らせ • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.お知らせ • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.すべての更新を表示Recent updatesBoard Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.お知らせ • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmarkお知らせ • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.お知らせ • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).お知らせ • Aug 21+ 1 more updateNovonesis A/S Approves Interim Dividend for First Half of 2025Novozymes A/S approved an interim dividend of 2.25 DKK (EUR 0.30) approved for the first half of 2025.お知らせ • Jun 02Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).Novonesis A/S (CPSE:NSIS B) agreed to acquire remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) for €1.5 billion on February 11, 2025. Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities. The transaction is accretive to Novonesis' revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies. dsm-firmenich expects to receive approximately €1.4 billion net in cash, after transaction costs and capital gains tax, and anticipates a book profit on the transaction to be recognized upon closing. Novonesis will continue a long-term commercial relationship with the Animal Nutrition & Health business, for the re-sale of its feed enzymes through the Animal Nutrition & Health world-class premix network. For the period ending December 31, 2024, Feed Enzymes Alliance of DSM-Firmenich AG reported total revenue of €300 million. Novonesis will continue the long-term supply relationship with DSM-Firmenich for their premix business. The acquisition is 100% debt financed and fully committed. The transaction is subject to regulatory approvals, the transaction is expected to close in the course of 2025. The expected strong cash generation will allow for deleveraging to the current target range of 1.3 to 1.7x net debt divided by EBITDA within the next 2 years. It is expected that the transaction will have no impact on dividend payouts. Gordon Dyal & Co acted as financial advisor, Baker McKenzie acted a legal advisor and financing is obtained through BNP Paribas to Novonesis. Piper Sandler acted as financial advisor to DSM-Firmenich AG. Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) on June 2, 2025. All regulatory approvals have been achieved. Gregory Crookes, Stephanie Horowitz, Pieter Leefers, Chris In t Veld, Marc Besen, Jurre Jurriëns, Gunnar Sachs, Claudia Milbradt, Nicolas Hohn-Hein, Floris van de Bult, Florence Aubonnet, Wijnanda Rutten and Michiel Sunderman of Clifford Chance Partnerschaftsgesellschaft, Clifford Chance France and Clifford Chance LLP acted as legal advisor to DSM-Firmenich AG.お知らせ • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).お知らせ • Apr 07Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026Novonesis A/S announced that they will report fiscal year 2025 results on Feb 25, 2026お知らせ • Apr 05+ 1 more updateNovonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its CommitteesNovonesis A/S at its Annual General Meeting held on April 3, 2025 approved election of Monila Kothari as a new member of the Board of Directors. Composition of the Board of Directors and its committees: After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee); Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee); Robert Nøddeskov Jensen (employee representative); Lise Kaae (chair of the Audit Committee); Monila Kothari (member of the Innovation Committee); Kasim Kutay (member of the Nomination and Remuneration Committee); Lars Bo Køppler (employee representative); Kevin Lane (member of the Innovation Committee); Preben Nielsen (employee representative and member of the Innovation Committee); Frederikke Rose Spenner (employee representative); Morten Otto Alexander Sommer (chair of the Innovation Committee) and Kim Stratton (member of the Nomination and Remuneration Committee).お知らせ • Mar 06Novonesis A/S Announces Board ChangesThe employees of Novonesis A/S have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly elected. Lars Bo Køppler, Technician - newly elected and Frederikke Rose Spenner, Production Engineer - newly elected. As alternates to the employee representatives to the Board of Directors, the employees elected Mikael Barfred, Heidi Gelt and Ida Carlsen Virklund. The newly elected employee representatives will join the Board of Directors following the Annual General Meeting of Novonesis on April 3, 2025. At the same event, the term of election for the former employee representatives, Lena Bech Holskov, Anders Hentze Knudsen, and Jens Øbro will end. The term of Board Observer Kim Ib Sørensen will also end following the Annual General Meeting of Novonesis on April 3, 2025.お知らせ • Feb 26+ 2 more updatesNovonesis A/S Proposes Dividend, Payable on April 8, 2025Novonesis A/S proposed dividend of DKK 4.20 per share (EUR 0.56) with the total pay-out for the year unchanged compared to previous year. The dividend will be disbursed on April 8, 2025, with April 3, 2025, as the last trading day with dividend. Total dividend pay-out for the year equals 65.1% of the adjusted net profit.お知らせ • Feb 21Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025Novonesis A/S announced that Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Jacob joined Chr. Hansen in 2006 and became a member of the Corporate Leadership Team in 2013. During his tenure in Chr. Hansen, Jacob has held multiple global sales and business unit leadership positions and since 2019 been responsible for the Food Cultures & Enzymes business unit, before entering his current role in Novonesis.お知らせ • Dec 17Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. Sharon James has expressed her gratitude for the opportunity to serve together with the Board and Management team with strong confidence in Novonesis’ future leadership and strategic vision.お知らせ • Nov 07+ 2 more updatesNovonesis A/S to Report First Half, 2025 Results on Aug 13, 2025Novonesis A/S announced that they will report first half, 2025 results on Aug 13, 2025お知らせ • Oct 21Novonesis A/S Announces Board ChangesNovonesis A/S announced that Anne Breum, one of the employee-elected members of the Board of Directors of Novozymes A/S, has decided to step down as a board member. The first alternate, Lena Bech Holskov (Safety Adviser, OHS) has replaced Anne Breum as employee-elected board member of the Company for the remaining period of the current four-year election term ending following the annual general meeting of the Company to be held on April 3, 2025.お知らせ • Aug 28Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024Novonesis approved interim dividend for 2024 at DKK 2.00 per share (EUR 0.27). The dividend will be disbursed on September 3, 2024, with August 29, 2024, as the last trading day with dividend.お知らせ • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.お知らせ • May 01Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced at the AGM held on April 30, 2024, approved distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.お知らせ • Apr 09Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced that at its AGM to be held on April 30, 2024, The distribution of profit will be addressed at the meeting and the board of directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 to December 31) of 2023. This equals a pay-out ratio of 53.2% of the company’s adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share (50.8% pay-out ratio). This equals an increase in the paid dividend of 3% compared to the dividend paid for the 2022 result.お知らせ • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.お知らせ • Feb 24+ 3 more updatesNovozymes A/S to Report First Half, 2024 Results on Aug 28, 2024Novozymes A/S announced that they will report first half, 2024 results on Aug 28, 2024お知らせ • Jun 30Novozymes A/S, Annual General Meeting, Mar 13, 2024Novozymes A/S, Annual General Meeting, Mar 13, 2024.業績と収益の成長予測BATS-CHIXE:NSISBC - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20285,0849649811,5061412/31/20274,7438488261,3821612/31/20264,4237287531,270163/31/20264,1995977741,282N/A12/31/20254,1585847511,222N/A9/30/20254,1425477451,123N/A6/30/20254,098565569918N/A3/31/20254,058459586950N/A12/31/20243,8343066601,020N/A9/30/20243,471314634941N/A6/30/20243,047283599891N/A3/31/20242,636334422692N/A12/31/20232,402406281557N/A9/30/20232,390430169485N/A6/30/20232,38246083436N/A3/31/20232,39048783476N/A12/31/20222,360494150539N/A9/30/20222,268460206554N/A6/30/20222,186418262539N/A3/31/20222,090416337530N/A12/31/20212,009423379546N/A9/30/20211,958427461593N/A6/30/20211,914409432564N/A3/31/20211,883389443577N/A12/31/20201,883380459585N/A9/30/20201,920415442521N/A6/30/20201,955405465536N/A3/31/20201,968439407482N/A12/31/20191,924422N/A428N/A9/30/20191,923411N/A460N/A6/30/20191,917434N/A505N/A3/31/20191,922417N/A477N/A12/31/20181,927432N/A493N/A9/30/20181,924427N/A515N/A6/30/20181,915429N/A490N/A3/31/20181,920423N/A501N/A12/31/20171,952419N/A546N/A9/30/20171,958421N/A533N/A6/30/20171,934412N/A522N/A3/31/20171,919414N/A547N/A12/31/20161,902410N/A517N/A9/30/20161,864394N/A488N/A6/30/20161,883394N/A437N/A3/31/20161,883384N/A450N/A12/31/20151,876378N/A447N/A9/30/20151,840366N/A395N/A6/30/20151,795353N/A443N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NSISBCの予測収益成長率 (年間14% ) は 貯蓄率 ( 3.4% ) を上回っています。収益対市場: NSISBCの収益 ( 14% ) はUK市場 ( 11.6% ) よりも速いペースで成長すると予測されています。高成長収益: NSISBCの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: NSISBCの収益 ( 6.6% ) UK市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: NSISBCの収益 ( 6.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NSISBCの 自己資本利益率 は、3年後には低くなると予測されています ( 8.9 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 15:24終値2026/05/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Novozymes A/S 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。28 アナリスト機関Alexander SloaneBarclaysCezara LozneanuBarclaysSebastian SatzBarclays25 その他のアナリストを表示
お知らせ • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).
お知らせ • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).
お知らせ • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
お知らせ • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Employee Representative Director Lars Koppler was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 24Novonesis A/S Approves Dividend on A and B ShareNovozymes A/S announced at the AGM held on March 23, 2026, approved distribution of profit with payment of an ordinary dividend of DKK 4.25 (corresponding to approximately EUR 0.57) per A and B share.
お知らせ • Feb 27Novozymes A/S, Annual General Meeting, Mar 23, 2026Novozymes A/S, Annual General Meeting, Mar 23, 2026, at 16:00 Romance Standard Time. Location: gammel venlighedsvej 14, dk-2970 hoersholm, Denmark
お知らせ • Feb 25+ 3 more updatesNovozymes A/S Proposes Dividend for Full Year 2025Novozymes A/S proposed dividend of DKK 4.25 per share. DKK 2.25 per share interim dividend paid August 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
お知らせ • Nov 06Novozymes A/S Revises Earnings Guidance for the Year 2025Novozymes A/S revised earnings guidance for the year 2025. For the year, the company expects organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in fourth quarter following favorable timing in third quarter. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%).
お知らせ • Aug 21+ 1 more updateNovonesis A/S Approves Interim Dividend for First Half of 2025Novozymes A/S approved an interim dividend of 2.25 DKK (EUR 0.30) approved for the first half of 2025.
お知らせ • Jun 02Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR).Novonesis A/S (CPSE:NSIS B) agreed to acquire remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) for €1.5 billion on February 11, 2025. Novonesis has reached an agreement with dsm-firmenich to dissolve the Feed Enzyme Alliance and take over its sales and distribution activities. The transaction is accretive to Novonesis' revenue growth, adjusted EBITDA margin and adjusted EPS excl. amortization, with attractive revenue synergies. dsm-firmenich expects to receive approximately €1.4 billion net in cash, after transaction costs and capital gains tax, and anticipates a book profit on the transaction to be recognized upon closing. Novonesis will continue a long-term commercial relationship with the Animal Nutrition & Health business, for the re-sale of its feed enzymes through the Animal Nutrition & Health world-class premix network. For the period ending December 31, 2024, Feed Enzymes Alliance of DSM-Firmenich AG reported total revenue of €300 million. Novonesis will continue the long-term supply relationship with DSM-Firmenich for their premix business. The acquisition is 100% debt financed and fully committed. The transaction is subject to regulatory approvals, the transaction is expected to close in the course of 2025. The expected strong cash generation will allow for deleveraging to the current target range of 1.3 to 1.7x net debt divided by EBITDA within the next 2 years. It is expected that the transaction will have no impact on dividend payouts. Gordon Dyal & Co acted as financial advisor, Baker McKenzie acted a legal advisor and financing is obtained through BNP Paribas to Novonesis. Piper Sandler acted as financial advisor to DSM-Firmenich AG. Novonesis A/S (CPSE:NSIS B) completed the acquisition of remaining 50% stake in Feed Enzymes Alliance from DSM-Firmenich AG (ENXTAM:DSFIR) on June 2, 2025. All regulatory approvals have been achieved. Gregory Crookes, Stephanie Horowitz, Pieter Leefers, Chris In t Veld, Marc Besen, Jurre Jurriëns, Gunnar Sachs, Claudia Milbradt, Nicolas Hohn-Hein, Floris van de Bult, Florence Aubonnet, Wijnanda Rutten and Michiel Sunderman of Clifford Chance Partnerschaftsgesellschaft, Clifford Chance France and Clifford Chance LLP acted as legal advisor to DSM-Firmenich AG.
お知らせ • May 08Novonesis A/S Maintains Earnings Guidance for the Year 2025Novonesis A/S maintained earnings guidance for the year 2025. For the year, company expected 5-8% organic sales growth (6-9% excluding the exit from certain countries).
お知らせ • Apr 07Novonesis A/S to Report Fiscal Year 2025 Results on Feb 25, 2026Novonesis A/S announced that they will report fiscal year 2025 results on Feb 25, 2026
お知らせ • Apr 05+ 1 more updateNovonesis A/S Approves Election of Monila Kothari as A Director and Composition of the Board of Directors and Its CommitteesNovonesis A/S at its Annual General Meeting held on April 3, 2025 approved election of Monila Kothari as a new member of the Board of Directors. Composition of the Board of Directors and its committees: After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees. The Board of Directors, including its committees, is now composed as follows: Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee); Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee); Robert Nøddeskov Jensen (employee representative); Lise Kaae (chair of the Audit Committee); Monila Kothari (member of the Innovation Committee); Kasim Kutay (member of the Nomination and Remuneration Committee); Lars Bo Køppler (employee representative); Kevin Lane (member of the Innovation Committee); Preben Nielsen (employee representative and member of the Innovation Committee); Frederikke Rose Spenner (employee representative); Morten Otto Alexander Sommer (chair of the Innovation Committee) and Kim Stratton (member of the Nomination and Remuneration Committee).
お知らせ • Mar 06Novonesis A/S Announces Board ChangesThe employees of Novonesis A/S have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly elected. Lars Bo Køppler, Technician - newly elected and Frederikke Rose Spenner, Production Engineer - newly elected. As alternates to the employee representatives to the Board of Directors, the employees elected Mikael Barfred, Heidi Gelt and Ida Carlsen Virklund. The newly elected employee representatives will join the Board of Directors following the Annual General Meeting of Novonesis on April 3, 2025. At the same event, the term of election for the former employee representatives, Lena Bech Holskov, Anders Hentze Knudsen, and Jens Øbro will end. The term of Board Observer Kim Ib Sørensen will also end following the Annual General Meeting of Novonesis on April 3, 2025.
お知らせ • Feb 26+ 2 more updatesNovonesis A/S Proposes Dividend, Payable on April 8, 2025Novonesis A/S proposed dividend of DKK 4.20 per share (EUR 0.56) with the total pay-out for the year unchanged compared to previous year. The dividend will be disbursed on April 8, 2025, with April 3, 2025, as the last trading day with dividend. Total dividend pay-out for the year equals 65.1% of the adjusted net profit.
お知らせ • Feb 21Novonesis Announces Jacob Vishof Paulsen Will Leave His Position as Executive Vice President of Food & Beverage Biosolutions, Effective March 31, 2025Novonesis A/S announced that Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Jacob joined Chr. Hansen in 2006 and became a member of the Corporate Leadership Team in 2013. During his tenure in Chr. Hansen, Jacob has held multiple global sales and business unit leadership positions and since 2019 been responsible for the Food Cultures & Enzymes business unit, before entering his current role in Novonesis.
お知らせ • Dec 17Novonesis A/S Announces That Sharon James Will Not Be Seeking Re-Election to the Board of Directors, Effectively on December 31, 2024Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. Sharon James has expressed her gratitude for the opportunity to serve together with the Board and Management team with strong confidence in Novonesis’ future leadership and strategic vision.
お知らせ • Nov 07+ 2 more updatesNovonesis A/S to Report First Half, 2025 Results on Aug 13, 2025Novonesis A/S announced that they will report first half, 2025 results on Aug 13, 2025
お知らせ • Oct 21Novonesis A/S Announces Board ChangesNovonesis A/S announced that Anne Breum, one of the employee-elected members of the Board of Directors of Novozymes A/S, has decided to step down as a board member. The first alternate, Lena Bech Holskov (Safety Adviser, OHS) has replaced Anne Breum as employee-elected board member of the Company for the remaining period of the current four-year election term ending following the annual general meeting of the Company to be held on April 3, 2025.
お知らせ • Aug 28Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024Novonesis approved interim dividend for 2024 at DKK 2.00 per share (EUR 0.27). The dividend will be disbursed on September 3, 2024, with August 29, 2024, as the last trading day with dividend.
お知らせ • May 03Novonesis Provides Sales Guidance for the Year 2024Novonesis provided sales guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
お知らせ • May 01Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced at the AGM held on April 30, 2024, approved distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.
お知らせ • Apr 09Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023Novozymes A/S announced that at its AGM to be held on April 30, 2024, The distribution of profit will be addressed at the meeting and the board of directors proposes an ordinary dividend of DKK 2 or EUR 0.27 per A/B share for the last four months (September 1 to December 31) of 2023. This equals a pay-out ratio of 53.2% of the company’s adjusted net profit for the four-month period. Following the approval of the proposed dividend, legacy Novozymes shareholders will have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share (50.8% pay-out ratio). This equals an increase in the paid dividend of 3% compared to the dividend paid for the 2022 result.
お知らせ • Mar 23Novonesis Provides Earnings Guidance for the Year 2024Novonesis provided earnings guidance for the year 2024. For the year, the company expects 5% to 7% organic sales growth.
お知らせ • Feb 24+ 3 more updatesNovozymes A/S to Report First Half, 2024 Results on Aug 28, 2024Novozymes A/S announced that they will report first half, 2024 results on Aug 28, 2024
お知らせ • Jun 30Novozymes A/S, Annual General Meeting, Mar 13, 2024Novozymes A/S, Annual General Meeting, Mar 13, 2024.